Dynavax Technologies Management
Management criteria checks 3/4
Dynavax Technologies' CEO is Ryan Spencer, appointed in Dec 2019, has a tenure of 5.08 years. total yearly compensation is $5.81M, comprised of 13.1% salary and 86.9% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth €2.86M. The average tenure of the management team and the board of directors is 4 years and 6.6 years respectively.
Key information
Ryan Spencer
Chief executive officer
US$5.8m
Total compensation
| CEO salary percentage | 13.1% |
| CEO tenure | 5.1yrs |
| CEO ownership | 0.2% |
| Management average tenure | 4yrs |
| Board average tenure | 6.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$20m |
| Jun 30 2024 | n/a | n/a | US$17m |
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$6m | US$760k | -US$6m |
| Sep 30 2023 | n/a | n/a | US$61m |
| Jun 30 2023 | n/a | n/a | US$111m |
| Mar 31 2023 | n/a | n/a | US$236m |
| Dec 31 2022 | US$6m | US$695k | US$293m |
| Sep 30 2022 | n/a | n/a | US$320m |
| Jun 30 2022 | n/a | n/a | US$228m |
| Mar 31 2022 | n/a | n/a | US$104m |
| Dec 31 2021 | US$5m | US$600k | US$72m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$2m | US$515k | -US$75m |
| Sep 30 2020 | n/a | n/a | -US$97m |
| Jun 30 2020 | n/a | n/a | -US$138m |
| Mar 31 2020 | n/a | n/a | -US$129m |
| Dec 31 2019 | US$3m | US$391k | -US$156m |
Compensation vs Market: Ryan's total compensation ($USD5.81M) is above average for companies of similar size in the German market ($USD1.50M).
Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.
CEO
Ryan Spencer (46 yo)
5.1yrs
Tenure
US$5,810,736
Compensation
Mr. Ryan Spencer serves as Independent Director at Cidara Therapeutics, Inc. from April 24, 2024. He serves as the Chief Executive Officer and Director of Dynavax Technologies Corporation since December 16...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.1yrs | US$5.81m | 0.17% € 2.9m | |
| President & COO | 11.8yrs | US$2.99m | 0.024% € 397.1k | |
| Senior VP & CFO | 3.8yrs | US$2.07m | 0.0059% € 95.6k | |
| Chief Medical Officer and Senior VP of Clinical Development | 11.5yrs | US$1.88m | 0.049% € 799.2k | |
| Chief Accounting Officer & Controller | 4.7yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | 6yrs | no data | no data | |
| VP of Investor Relations & Corporate Communications | 2yrs | no data | no data | |
| Senior VP & General Counsel | 3.6yrs | no data | no data | |
| Senior VP & Chief Commercial Officer | no data | no data | no data | |
| Senior Vice President of Research | 3.9yrs | no data | no data | |
| VP, Site Head & MD for Dynavax GmbH | 4yrs | no data | no data | |
| Senior Vice President of Technical Operations | 4yrs | no data | no data |
4.0yrs
Average Tenure
59.5yo
Average Age
Experienced Management: DYF1's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.1yrs | US$5.81m | 0.17% € 2.9m | |
| Independent Director | 18.4yrs | US$298.73k | 0.021% € 345.0k | |
| Independent Director | 14.5yrs | US$290.73k | 0.0011% € 18.6k | |
| Independent Director | 15.2yrs | US$278.73k | 0.016% € 259.1k | |
| Member of Scientific Advisory Board | 2yrs | US$1.83m | no data | |
| Member of Scientific Advisory Board | 6.6yrs | no data | no data | |
| Independent Director | 4.5yrs | US$293.73k | 0% € 0 | |
| Member of Scientific Advisory Board | 6.6yrs | US$20.00k | no data | |
| Independent Chairman of the Board | 3.3yrs | US$323.73k | 0% € 0 | |
| Member of Scientific Advisory Board | 6.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.6yrs | no data | no data |
6.6yrs
Average Tenure
73.5yo
Average Age
Experienced Board: DYF1's board of directors are considered experienced (6.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 13:43 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dynavax Technologies Corporation is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Elemer Piros | Cantor Fitzgerald & Co. |
| Joshua Schimmer | Evercore ISI |
| Jonathan Miller | Evercore ISI |